title: Development of RNA interference-based therapeutics and application of multi-target small interfering RNAs.
abstract: RNA interference (RNAi) has been proven in recent years to be a newly advanced and powerful tool for development of therapeutic agents toward various unmet medical needs such as cancer, in particular, a great attention has been paid to the development of antineoplastic agents. Recent success in clinical trials related to RNAi-based therapeutics on cancer and ocular disease has validated that small interfering RNAs (siRNAs) constitute a new promising class of therapeutics. Currently, a great wealth of multi-target based siRNA structural modifications is available for promoting siRNA-mediated gene silencing with low side effects. Here, the latest developments in RNAi-based therapeutics and novel structural modifications described for siRNAs--in particular multi-target siRNAs--are reviewed.
authors.affiliation: 1 Department of Pathological Anatomy, Nantong University , Nantong, China .
authors.forename: Tiejun
authors.initials: T
authors.lastname: Li
authors.forename: Meihua
authors.initials: M
authors.lastname: Wu
authors.forename: York Yuanyuan
authors.initials: YY
authors.lastname: Zhu
authors.forename: Jianxin
authors.initials: J
authors.lastname: Chen
authors.forename: Li
authors.initials: L
authors.lastname: Chen
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D016503:Drug Delivery Systems / Q000379:methods; D015352:Dry Eye Syndromes / Q000628:therapy*; D006801:Humans; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000628:therapy*; D009690:Nucleic Acid Conformation; D034622:RNA Interference; D034741:RNA, Small Interfering / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D034741:RNA, Small Interfering